Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €174.17 EUR
Change Today -0.83 / -0.48%
Volume 0.0
As of 11:55 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BR6) Snapshot

Open
€173.44
Previous Close
€175.01
Day High
€175.29
Day Low
€173.43
52 Week High
08/6/15 - €185.02
52 Week Low
09/29/14 - €111.81
Market Cap
12.9B
Average Volume 10 Days
46.8
EPS TTM
--
Shares Outstanding
74.2M
EX-Date
07/16/15
P/E TM
--
Dividend
€0.99
Dividend Yield
0.45%
Current Stock Chart for CR BARD INC (BR6)

cr bard inc (BR6) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BR6) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products that include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as other products, such as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,900 Employees
Last Reported Date: 02/18/15
Founded in 1907

cr bard inc (BR6) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $594.5K
Group President
Total Annual Compensation: $594.5K
Group President
Total Annual Compensation: $592.1K
Compensation as of Fiscal Year 2014.

cr bard inc (BR6) Key Developments

CR Bard Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter of 2015; Revises Earnings Guidance for the Full Year 2015

CR Bard Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss available to common shareholders of USD 54,700,000 or USD 0.74 per basic and diluted share on net sales of USD 859,800,000 compared to net loss available to common shareholders of USD 119,400,000 or USD 1.59 per basic and diluted share on net sales of USD 827,100,000 for the last year. The company reported income from operations before income taxes of USD 59,200,000 compared to loss from operations before income taxes of USD 92,800,000 for the last year. Adjusted net income available to common shareholders was USD 171,100,000 or USD 2.27 per diluted share against USD 158,000,000 or USD 2.06 per diluted share a year ago. Capital expenditures totaled USD 28.4 million in the quarter. For the six months, the company reported net income available to common shareholders of USD 83,900,000 or USD 1.11 per diluted share on net sales of USD 1,679,500,000 compared to net income available to common shareholders of USD 28,600,000 or USD 0.37 per diluted share on net sales of USD 1,626,400,000 for the last year. The company reported income from operations before income taxes of USD 243,800,000 compared to USD 90,800,000 for the last year. Adjusted net income available to common shareholders was USD 330,300,000 or USD 4.36 per diluted share against USD 308,100,000 or USD 3.98 per diluted share a year ago. For the third quarter of 2015, the company is expecting constant currency sales growth between 6% and 7% and organic sales growth between 6.5% and 7.5%. The company expected the Gore royalty to decline compared to the prior year due to foreign exchange. From an EPS standpoint, excluding items affecting comparability, the company expected the third quarter in the range of USD 2.21 to USD 2.25 per share, reflecting a somewhat lower gross margin and the higher R&D spend compared to the second quarter of 2015 in the prior year. For the full year 2015, the company now expected constant currency sales growth to be between 5% and 6% and organic sales growth to be between 5.5% and 6.5%, which is a full 150 basis point improvement from original guidance in January. And the company now expected foreign exchange to reduce sales for both third quarter of 2015 and the full year 2015 by about 350 basis points. For the full year 2015, the company is increasing adjusted EPS guidance by USD 0.05 to a range of USD 9 to USD 9.10. This higher range reflects modest dilution from a recent acquisition and the increased investments the company expected to make in SG&A and R&D during the second half of 2015.

CR Bard Inc. to Report Q2, 2015 Results on Jul 23, 2015

CR Bard Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 23, 2015

CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015

CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BR6:GR €174.17 EUR -0.83

BR6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Coloplast A/S kr453.10 DKK +1.90
Edwards Lifesciences Corp $142.74 USD -1.96
Endo International PLC $77.88 USD -0.82
Sigma-Aldrich Corp $139.55 USD 0.00
Smith & Nephew PLC 1,163 GBp +29.00
View Industry Companies
 

Industry Analysis

BR6

Industry Average

Valuation BR6 Industry Range
Price/Earnings 43.6x
Price/Sales 4.3x
Price/Book 8.8x
Price/Cash Flow 41.8x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.